IL10 and neoplasm: In aggressive cancers, TLS may foster immunosuppression through: (1) cytokine-mediated inhibitory microenvironments; (2) TLS-resident Tregs that dampen anti-tumor T cell responses; and (3) IL-10-secreting B cells that impair tumor-specific immunity.